BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

VOLUNTARY ANNOUNCEMENT

THE KEY TECHNOLOGY OF BIOCYTOGEN'S FULLY HUMAN ANTIBODY RENMAB® PLATFORM HAS BEEN GRANTED A CHINESE PATENT

The board (the "**Board**") of directors (the "**Directors**") of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**" or "**Biocytogen**", together with its subsidiaries, the "**Group**") is pleased to announce its independently self-developed key technology of RenMab platform has been granted a Chinese patent (the "**Patent**"). The Patent is related to the key technology of Biocytogen's fully human antibody RenMab® platform and the Company has recently received the patent certificate issued by the China National Intellectual Property Administration. The RenMab technology platform is used to directly obtain fully human antibodies from immunized mice, which greatly improved the efficiency of developing fully human antibody drugs and accelerated the developing progress. The Patent required by RenMab® platform further solidifies Biocytogen's competitiveness in the field of antibody drug development. Previously, the Company has submitted the patent applications for the RenMab platform in China, the United States, Europe, Japan, Singapore, Russia, Israel, Australia, and other countries and regions. Other than the Patent application for the RenMab platform is granted in China, the applications in other countries mentioned in the above are in progress.

Details of the Patent are set out below:

Patent Name:	Genetically modified non-human animals with humanized immunoglobulin locus
Type:	China Invention Patent
Patent Number:	ZL202080002761.4
Date of Application:	18 February 2020
Date of Expiry:	18 February 2040

The Patent of the key technology of RenMab platform demonstrates Biocytogen's outstanding innovation ability and robust intellectual property protection system. It is also an important guarantee for us to continue supporting worldwide partners with intellectual property rights protected. In the future, we will continue to engage in global patent strategies and protect key technologies. We look forward to obtaining more patent authorizations for the subsequent RenLite®, RenNano®, and other Biocytogen's proprietary fully human antibody mouse platforms.

This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, 11 July 2023

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.

The key technology of Biocytogen's fully human antibody RenMab® platform has been granted a Chinese patent

Beijing, China – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("**Biocytogen**" or "**Company**") (Stock Code: 02315.HK) announced its independently self-developed key technology of RenMab platform has been granted a Chinese patent (the "**Patent**"). The Patent is related to the key technology of Biocytogen's fully human antibody RenMab® platform and the Company has recently received the patent certificate issued by the China National Intellectual Property Administration. The RenMab technology platform is used to directly obtain fully human antibodies from immunized mice, which greatly improved the efficiency of developing fully human antibody drugs and accelerated the developing progress. The Patent required by RenMab® platform further solidifies Biocytogen's competitiveness in the field of antibody drug development. Previously, the Company has submitted the patent applications for the RenMab platform in China, the United States, Europe, Japan, Singapore, Russia, Israel, Australia, and other countries and regions. Other than the Patent application for the RenMab platform is granted in China, the applications in other countries mentioned in the above are in progress.

Using Biocytogen's independently developed Size-Unlimited and Precise Chromosome Engineering (**SUPCE®**) technology, the Company replaced the genes encoding the whole variable regions of both heavy and light chains of mouse antibodies with human counterparts in situ to generate fully human antibody mouse RenMab that possesses the complete human antibody heavy VDJ and light VJ genes. The RenMab platform, independently developed by Biocytogen, is one of the leading mouse platforms in the world that have complete human antibody variable region gene replacement. It is capable of generating fully human monoclonal antibodies that exhibit high diversity, specificity, affinity and excellent physiochemical properties.

In addition to RenMab platform, Biocytogen's independently developed fully human antibody RenMice® platforms also include RenLite® and RenNano® mouse platforms, as well as platforms with sub-series modifications on the basis of RenMice, which constituted a full range of technology platforms for the development of multiple forms of drug molecules including but not limited to fully human monoclonal antibodies, bispecific antibodies, antibody-drug-conjugates (ADCs), and fully human nanobodies, and can support the diverse research and development needs of pharmaceutical companies worldwide.

Since its release in 2019, the RenMice platforms have gained worldwide recognition in the biotech and biopharmaceutical industry. We have reached RenMice licensing agreements with dozens of companies, including but not limited to Merck KGaA, Janssen, Xencor, BeiGene, Innovent, Junshi Biosciences and Remegen.

Based on the RenMice platforms, Biocytogen launched the Project Integrum to develop antibody-based drugs for more than 1,000 targets. It is anticipated that this project will result in a library containing hundreds of thousands of fully human antibody sequences, to meet pharmaceutical companies' demands of novel drug development. As of 30 June 2023, 50 therapeutic antibody development cooperations have been established worldwide and these agreements encompass various drug modalities, including monoclonal antibodies, bispecific and multi-specific antibodies, ADCs, cell therapy, etc.

The Patent of the key technology of RenMab technology platform demonstrates Biocytogen's outstanding innovation ability and robust intellectual property protection system. It is also an important guarantee for us to continue supporting worldwide partners with intellectual property rights protected. In the future, we will continue to engage in global patent strategies and protect key technologies. We look forward to obtaining more patent authorizations for the subsequent RenLite, RenNano, and other Biocytogen's proprietary fully human antibody mouse platforms.

About Biocytogen

Biocytogen (Stock Code: 02315.HK) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Biocytogen is committed to becoming the global birthplace of new drugs, with the mission of focusing on technological innovation, continuous new drug output and guarding human health. Using its independently self-developed RenMice® platform (including RenMab®, RenLite®, RenNano® mice) with fully independent intellectual property rights for fully human monoclonal, Biocytogen has organicly integrated monoclonal antibody, bispecific/multispecific antibody and nanobody development platforms, its *in vivo* drug efficacy screening platforms and strong clinical development expertise to form a unique new drug research and development capability covering the whole process of drug research and development. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1,000 targets, known as Project Integrum. As of 30 June 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMice licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. In the future, Biocytogen will continue to work with global partners to produce many antibody drugs to better benefit patients. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg).

For more information, please visit our website at http://en.biocytogen.com.cn.

Forward-Looking Statements

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.